| Product Code: ETC4720351 | Publication Date: Nov 2023 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
The import shipments of human insulin to Israel in 2024 continued to be dominated by top exporting countries including Switzerland, USA, Germany, China, and Belgium. Despite a decline in the Compound Annual Growth Rate (CAGR) from 2020-2024, the industry saw a positive growth rate in 2024. The High Herfindahl-Hirschman Index (HHI) indicates a high concentration in the market, suggesting potential challenges for market competition and pricing dynamics in the coming years. Israel`s reliance on these key exporting countries underscores the importance of monitoring global trends and developments in the human insulin market.

The human insulin market in Israel supplies insulin products for the treatment of diabetes. This market includes various forms of insulin such as rapid-acting, long-acting, and biosimilar insulin. The market growth is driven by the increasing prevalence of diabetes, advancements in insulin delivery systems, and the demand for effective diabetes management solutions.
Increasing prevalence of diabetes, advancements in insulin delivery systems, and rising healthcare expenditure are driving market growth.
Despite advances in diabetes treatment, access to affordable human insulin remains a challenge for many patients in Israel. Addressing issues of affordability, availability, and quality assurance is crucial for improving healthcare outcomes and reducing the burden of chronic disease.
Israel promotes access to affordable and quality insulin products for individuals living with diabetes through regulatory frameworks, healthcare subsidies, and public health programs. Government policies aim to ensure availability, affordability, and safety of human insulin formulations for diabetes management.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Human Insulin Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Human Insulin Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Human Insulin Market - Industry Life Cycle |
3.4 Israel Human Insulin Market - Porter's Five Forces |
3.5 Israel Human Insulin Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Israel Human Insulin Market Revenues & Volume Share, By Diabetes Type, 2021 & 2031F |
3.7 Israel Human Insulin Market Revenues & Volume Share, By Delivery Devices, 2021 & 2031F |
3.8 Israel Human Insulin Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 Israel Human Insulin Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in Israel |
4.2.2 Growing aging population leading to higher demand for human insulin |
4.2.3 Technological advancements in insulin delivery devices |
4.3 Market Restraints |
4.3.1 Stringent government regulations for drug approval and pricing |
4.3.2 High cost of insulin therapy for patients |
4.3.3 Limited awareness about diabetes management and treatment options |
5 Israel Human Insulin Market Trends |
6 Israel Human Insulin Market Segmentations |
6.1 Israel Human Insulin Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Human Insulin Market Revenues & Volume, By Analogue Insulin, 2021-2031F |
6.1.3 Israel Human Insulin Market Revenues & Volume, By Traditional Human Insulin, 2021-2031F |
6.2 Israel Human Insulin Market, By Diabetes Type |
6.2.1 Overview and Analysis |
6.2.2 Israel Human Insulin Market Revenues & Volume, By Type 1 Diabetes, 2021-2031F |
6.2.3 Israel Human Insulin Market Revenues & Volume, By Type 2 Diabetes, 2021-2031F |
6.2.4 Israel Human Insulin Market Revenues & Volume, By Gestational Diabetes, 2021-2031F |
6.2.5 Israel Human Insulin Market Revenues & Volume, By Prediabetes, 2021-2031F |
6.3 Israel Human Insulin Market, By Delivery Devices |
6.3.1 Overview and Analysis |
6.3.2 Israel Human Insulin Market Revenues & Volume, By Syringes, 2021-2031F |
6.3.3 Israel Human Insulin Market Revenues & Volume, By Pens, 2021-2031F |
6.3.4 Israel Human Insulin Market Revenues & Volume, By Pumps, 2021-2031F |
6.3.5 Israel Human Insulin Market Revenues & Volume, By Others, 2021-2031F |
6.4 Israel Human Insulin Market, By End-users |
6.4.1 Overview and Analysis |
6.4.2 Israel Human Insulin Market Revenues & Volume, By Home Healthcare, 2021-2031F |
6.4.3 Israel Human Insulin Market Revenues & Volume, By Hospitals, 2021-2031F |
6.4.4 Israel Human Insulin Market Revenues & Volume, By Over The Counter (OTC), 2021-2031F |
6.4.5 Israel Human Insulin Market Revenues & Volume, By Clinics, 2021-2031F |
6.4.6 Israel Human Insulin Market Revenues & Volume, By Others, 2021-2031F |
7 Israel Human Insulin Market Import-Export Trade Statistics |
7.1 Israel Human Insulin Market Export to Major Countries |
7.2 Israel Human Insulin Market Imports from Major Countries |
8 Israel Human Insulin Market Key Performance Indicators |
8.1 Number of new diabetes cases diagnosed annually in Israel |
8.2 Adoption rate of advanced insulin delivery devices in the market |
8.3 Percentage of healthcare professionals trained in diabetes management in Israel |
9 Israel Human Insulin Market - Opportunity Assessment |
9.1 Israel Human Insulin Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Israel Human Insulin Market Opportunity Assessment, By Diabetes Type, 2021 & 2031F |
9.3 Israel Human Insulin Market Opportunity Assessment, By Delivery Devices, 2021 & 2031F |
9.4 Israel Human Insulin Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 Israel Human Insulin Market - Competitive Landscape |
10.1 Israel Human Insulin Market Revenue Share, By Companies, 2024 |
10.2 Israel Human Insulin Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |